receiving piperacillin-tazobactam (12.3%) versus meropenem (3.7%). 5 Such data should have been discussed. Likewise, no information is provided on treatment duration or dose, which may have varied between the 2 groups in the present study. 1 Both factors play a role in the outcome of treatment, especially when used against multidrug-resistant organisms. 6 Interestingly, we previously showed that BSI severity or mortality among spinal cord injury patients over 15 years was not related to the multidrug-resistant characteristics of the microorganism. 7 Although our sample size was small (n < 30), a closer look at the outcome between ESBL-EC (n = 26) and ESBL-KP (n = 13) did not reveal any statistical difference in terms of mortality rate (7.7% in each arm). Moreover, the mortality rates were similar for other ESBL microorganisms (Enterobacter spp, Morganella spp, and Proteus spp (n =21)),~9.5% (P = .99, data not shown).
In fact, we believe that the findings of Scheuerman et al, which showed no impact of CTX-M isolates in comparison to other ESBL genotypes, might support the idea that the type of germ does not play a major role. Indeed, mortality seems more related to patient comorbidities and severity of infection, as shown in Table 2 of the article, 1 with significant discrepancies between the 2 groups in terms of length of stay to bacteremia (P = .017), source of infection (P = .005), ICU ward admission (P < .001) and underlying cardiovascular disease (P < .001). Moreover, in a rabbit model of sepsis induced by a multidrug-resistant Klebsiella pneumoniae, Zhou et al 8 showed that mortality was higher for the rabbits infected by susceptible than those infected with multidrug-resistant strains.
Overall, the impact of ESBL-KP isolates on mortality rate might have been overestimated, in the light of the severity of the patient condition.
Differences in mortality between infections due to extendedspectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli To the Editor-We read with interest the recent article by Scheuerman et al, 1 in which they found that patients with extended-spectrum-β-lactamase (ESBL) producing Klebsiella pneumoniae infections had higher 30-day mortality than patients with ESBL producing Escherichia coli infections. We have recently published on mortality, readmissions, recurrences, and the benefit of infectious diseases consultation for patients with various multidrug resistant organism infections. 2, 3 We included in our study patients with various ESBL producing Enterobacteriaceae infections, among them K. pneumoniae and E. coli. Given the recent findings of Scheuerman et al, we conducted a retrospective evaluation to determine the association between ESBL producing organism (K. pneumoniae or E. coli) and 30-day all-cause mortality at our institution. This study was conducted at Barnes-Jewish Hospital, a 1,250bed academic medical center in St Louis, Missouri. The study period was January 1, 2006, to October 1, 2015. We included patients with positive sterile site and bronchial wash/bronchoalveolar lavage cultures for ESBL-producing E. coli and K. pneumoniae. Sterile sites were defined as bloodstream; pleural, intra-abdominal, pericardial, cerebrospinal, and synovial fluids; bone marrow; and surgical specimens collected from lymph nodes, central nervous system, liver, spleen, kidney, pancreas, ovary, or vascular tissue. The presence of ESBL production was assumed based on ceftriaxone, aztreonam, cefotaxime, or ceftazidime nonsusceptibility. 4 The Washington University School of Medicine Institutional Review Board approved this study with a waiver of informed consent.
The primary endpoint was 30-day all-cause mortality. Kaplan-Meier curves for 30-day all-cause mortality were generated to compare organism type and significance determined using the log-rank test. Escherichia coli was used as the reference group for determining the association between organism and mortality. Log-log survival plots were used to graphically test the proportional hazards assumption. Factors associated with mortality in bivariate analysis (P < .20) were entered into a multivariate Cox proportional hazards model to determine hazard ratios (HR) for 30-day all-cause mortality. All analyses were conducted with SPSS version 25 software (IBM, Armonk, NY).
In total, 605 patients met the eligibility criteria: 543 with ESBL E. coli and 62 with ESBL K. pneumoniae. Among patients with ESBL E. coli, 96 (17.7%) died within 30 days compared to 16 (25.8%) with ESBL K. pneumoniae. In Kaplan-Meier analysis, mortality was not significantly different between patients infected with K. pneumoniae and E. coli ESBL organisms (P = 0.12). Variables retained in the final Cox proportional hazards model are shown in Table 1 . Infection with ESBL-producing K. pneumoniae was marginally associated with mortality in the final Cox proportional hazards model (hazard ratio [HR], 1.69; 95% confidence interval [CI], 0.97-2.92; P = .062). Because the number of patients in the ESBL K. pneumoniae group was small, we performed a post-hoc power analysis and found that we had only 35.8% power to detect a significant difference in mortality.
Our results add to the body of literature on differences in mortality between ESBL-producing K. pneumoniae and E. coli. Despite the low power of our study, ESBL-producing K. pneumoniae was associated with marginally increased risk of 30-day mortality. Our data are important to add to the literature on this subject and could be combined with the data of Scheuerman et al and future studies in a meta-analysis to more definitively determine the association between ESBL-producing organism type and mortality. In addition, as demonstrated in our previous study, infectious disease consultation was associated with reduced mortality for drug-resistant Enterobacteriaceae infections. 
